Lactoferrin

Compound Class	Iron-binding glycoprotein (transferrin family) — a protein, not a small molecule; no meaningful CAS applies
Molecular Weight	~80 kDa; binds two Fe³⁺ ions with very high affinity
Source	Bovine milk (cheese whey or skim milk); also present in human milk, saliva, tears, and neutrophils
Iron Saturation Forms	Apo-lactoferrin (iron-free) vs holo-lactoferrin (iron-saturated) — a critical and under-specified distinction
Typical Standardisation	Lactoferrin by RP-HPLC or ELISA; 98% high-purity and 10% grades
Primary Applications	Iron-deficiency anaemia; infant formula; immune and gut-barrier formulation
Claim Strength (Overview)	Moderate for iron-deficiency anaemia (comparable to ferrous sulfate, better tolerated); mixed-to-null for neonatal sepsis prevention
Buy from Herbuno	Lactoferrin Powder (98%) → Lactoferrin Powder (10%) →

Name origin: Lactoferrin is named for its two defining properties: it was isolated from milk (lacto-) and it binds iron (-ferrin). It is a member of the transferrin family, an ~80 kDa glycoprotein that binds two ferric ions with extraordinarily high affinity — roughly three hundred times that of serum transferrin, and importantly, it retains iron even at the low pH of inflamed or infected tissue, where transferrin releases it. Traditional use: None as an isolated protein, though human milk — in which lactoferrin is a major protein — has been the object of every traditional infant-feeding practice in history. Lactoferrin was isolated in 1960 and its structure and functions elucidated through the following decades. Research trajectory: Lactoferrin research has followed two threads: iron (as a gentler, better-tolerated iron delivery vehicle than inorganic salts) and host defence (as an antimicrobial and immunomodulatory protein of the innate immune system). The iron thread has produced the more convincing human trial data; the host-defence thread has produced a large mechanistic literature and some genuinely disappointing large clinical trials, both of which this page reports. Commercial source: Bovine lactoferrin isolated from cheese whey or skim milk.

---

Evidence for Lactoferrin Applications

The strongest and most commercially useful human evidence is in iron-deficiency anaemia, and it is a comparative rather than a placebo result. A prospective, randomized, controlled, double-blind trial in 100 pregnant women with iron-deficiency anaemia compared bovine lactoferrin at 100 mg twice daily against ferrous sulfate 520 mg once daily, evaluating haemoglobin, serum ferritin, serum iron and total iron-binding capacity after 30 days; the results showed that bovine lactoferrin has the same efficacy as ferrous sulfate in restoring iron deposits, with significantly fewer gastrointestinal side effects (Paesano 2009). Equal efficacy at a fifth of the elemental dose with better tolerability is a genuinely useful commercial proposition, and the gastrointestinal tolerability of oral iron is a real clinical problem. Claim strength: Moderate.

The neonatal sepsis story must be told honestly, because it is where the biggest hopes were placed and where the results disappointed. A randomized double-blind controlled trial in 414 neonates with birth weight 500–2000 g across three neonatal units in Lima, Peru, compared bovine lactoferrin at 200 mg/kg/day against placebo for eight weeks; late-onset sepsis or sepsis-associated death occurred in 22 (10.5%) of the lactoferrin group versus 30 (14.6%) of placebo — but there was no difference after adjusting for hospital and birth weight (hazard ratio 0.73, 95% CI 0.42–1.26) (Ochoa 2020). A confidence interval crossing 1 is a null result, and the large UK ELFIN trial reached similar conclusions. Claim strength: Emerging — the neonatal sepsis claim is not established.

The mechanistic repertoire is genuinely broad and well characterised, which is what makes the clinical disappointments so instructive. Lactoferrin has bacteriostatic effects through iron sequestration (starving pathogens of iron), disrupts bacterial cell membranes by binding lipopolysaccharide in gram-negative bacteria, binds pathogen-host cell receptors, inhibits biofilm formation, modulates intestinal flora, promotes intestinal cell proliferation, differentiation and maturation, regulates immune response, and has antioxidative effects. This is a real and multi-layered innate-immune protein — and a rich mechanism list does not guarantee a clinical endpoint. Claim strength: High (mechanistic); Emerging (clinical translation).

The specification point that buyers almost never raise: iron saturation. Lactoferrin exists as apo-lactoferrin (iron-free) and holo-lactoferrin (iron-saturated), and commercial bovine lactoferrin is typically only 10–20% iron-saturated. This matters because the two forms behave differently — apo-lactoferrin is the form that sequesters free iron and starves pathogens, and its antimicrobial activity depends on having empty iron-binding sites. A highly saturated material has fewer free sites. Yet iron saturation is rarely stated on a certificate of analysis, and a buyer relying on antimicrobial mechanism should ask for it. Claim strength: High (compositional fact).

Gastric survival is the other under-discussed constraint. Lactoferrin is a protein and is susceptible to pepsin digestion at gastric pH; the iron-saturated holo form is notably more resistant to proteolysis than the apo form, which creates a genuine tension — the form with the better antimicrobial mechanism is the form less likely to survive the stomach intact. Partial hydrolysis also generates lactoferricin, a peptide with its own potent antimicrobial activity, so digestion is not purely destructive. This is a more complicated pharmacokinetic picture than "take lactoferrin, get lactoferrin," and formulators should engage with it. Claim strength: Moderate.

---

Dosage & Formulator Specification

Herbuno carries Lactoferrin Powder at 98% (high-purity) and 10% grades. Buyers should specify the iron saturation required — apo (iron-free) versus holo (iron-saturated) — as this is functionally consequential and is not captured by a purity figure. Herbuno will discuss saturation requirements at enquiry.

Human trial dosing has been indication-specific. For iron-deficiency anaemia in the pregnancy trial cited above, bovine lactoferrin was given at 100 mg twice daily (200 mg/day) and matched ferrous sulfate 520 mg/day for efficacy with better tolerability. Infant-formula supplementation has used roughly 1 g/L, benchmarked against human milk. The neonatal sepsis trials used 150–300 mg/day or 200 mg/kg/day — and produced null results, so those doses should not be cited as validated. Adult immune-support dosing rests on considerably weaker foundations and no figure should be presented as clinically established.

Analytical verification should specify lactoferrin content by RP-HPLC or ELISA and, critically, the iron saturation percentage, which is functionally determinative and routinely omitted. Because lactoferrin is a protein, conformational integrity governs activity: pasteurisation and spray-drying conditions, pH history, and heat exposure all matter, and a mass-based assay can pass while the protein is denatured. Request functional data or at minimum documented processing conditions. Standard dairy-allergen declaration applies, along with microbiological and, for whey-derived material, appropriate residue testing.

Bovine lactoferrin has GRAS status in several jurisdictions and an extensive safety record in infant formula and food; the large neonatal trials found it well tolerated, and the anaemia trial found it produced fewer gastrointestinal side effects than ferrous sulfate. Two points warrant statement. It is a bovine milk protein and therefore a regulated dairy allergen requiring clear declaration; individuals with cow’s milk protein allergy should avoid it. And second, a supplier should be candid that the neonatal sepsis prevention claim — the application on which lactoferrin generated the most excitement — did not hold up in large randomized trials, and that positioning a product on it would not be supportable.

---

Frequently Asked Questions — Lactoferrin

Does lactoferrin work for iron deficiency?
This is its best human evidence. A randomized double-blind trial in 100 pregnant women with iron-deficiency anaemia found bovine lactoferrin at 200 mg/day had the same efficacy as ferrous sulfate 520 mg/day in restoring iron stores — with significantly fewer gastrointestinal side effects. Given how poorly oral iron is tolerated, that is a genuinely useful proposition.

Does lactoferrin prevent neonatal sepsis?
It did not hold up. A 414-infant randomized trial found late-onset sepsis in 10.5% of the lactoferrin group versus 14.6% of placebo — but no difference after adjustment, with a hazard ratio of 0.73 and a confidence interval crossing 1. The large UK ELFIN trial reached similar conclusions. This was the application with the biggest hopes.

What is apo- versus holo-lactoferrin?
Iron-free versus iron-saturated, and it matters more than buyers realise. Apo-lactoferrin is the form that sequesters free iron and starves pathogens — its antimicrobial activity depends on having empty binding sites. Commercial bovine lactoferrin is typically only 10-20% saturated, but saturation is rarely stated on a certificate. Ask for it.

Does lactoferrin survive the stomach?
Partly, and it is more complicated than it looks. Lactoferrin is susceptible to pepsin digestion, and the iron-saturated holo form resists proteolysis better than the apo form — meaning the form with the better antimicrobial mechanism is less likely to survive intact. Partial hydrolysis also generates lactoferricin, itself a potent antimicrobial peptide, so digestion is not purely destructive.

Related compounds: Immunoglobulin Y, L-Glutathione, Beta-Glucans, Polysaccharides

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery